Abstract
The recent approval of cetuximab and bevacizumab by FDA for the treatment of metastatic colorectal cancer witnesses the investments of biotech companies in the development of monoclonal antibodies (Mabs) as cancer therapeutics. Several analyses point to the growth of the market for these drugs, and forecast an even higher expansion of sales following completion of several clinical trials, both of approved Mabs tested for other cancers, and of new Mabs aimed at different tumor antigens. Not unsurprisingly, the latest additions to the number of therapeutic Mabs belong to the classes of chimeric and humanized antibodies. A great effort has been made in the last years to overcome the intrinsic limitations of the technology used to produce monoclonal antibodies. The knowledge accumulated in the search of newer ways of production of recombinant therapeutic proteins is reflected by the number of fully human Mabs in the pipeline. Moreover, a thorough understanding of the cellular and molecular events underlying the activity of cancer-aimed antibodies allows the optimisation of these drugs for the treatment of high incidence solid tumors.
Citations
Oct 18, 2005·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Hollins P ClarkRonald J Zagoria
Aug 2, 2006·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Christopher P Stowell
Mar 14, 2007·Vox Sanguinis·C V SapanR L Lundblad
Dec 17, 2009·Expert Opinion on Investigational Drugs·Nagathihalli S Nagaraj, Pran K Datta
Oct 2, 2014·International Journal of Oncology·Allen CohnDonald Richards
Apr 11, 2006·Cancer Gene Therapy·Y Shen, J Nemunaitis
Jun 14, 2013·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Rachel ShukrunBenjamin Dekel
Jul 12, 2005·Expert Opinion on Investigational Drugs·Michael LahnBrandi S Berry
May 13, 2008·Expert Review of Anticancer Therapy·Richard G EversonJohn H Sampson
Jul 1, 2008·The Oncologist·Christine H Chung
Jun 11, 2005·Pharmaceutical Research·Dawn N WaterhouseMarcel B Bally
Jun 20, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna L SmithHeide L Ford
Oct 11, 2005·Drug Discovery Today·Evelyn WolfPatrick A Baeuerle